Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brensocatib QT Interval Study
NCT05355935Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of brensocatib in Non-cystic fibrosis bronchiectasis (NCFB) (3 arms), sponsored by Insmed Incorporated. Primary endpoints: Number of Participants who Experienced at least one Treatment-Emergent Adverse Event and Placebo- and Baseline-Corrected QTcF (ΔΔQTcF). Started Apr 2022; status: completed.
02
Drugs
brensocatib
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT05355935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355935.